About this trial
The purpose of this trial is to investigate how proteins and genes respond to pancreatic cancer treatment.
The first aim is to identify predictive biomarkers in plasma and tissue that respond to pancreatic cancer treatment
The second aim is to
– Confirm a set of identified predictive biomarkers that respond to pancreatic cancer treatment and
– Further understand how specific proteins respond to disease progression.
Pancreatic cancer patients who will receive standard treatment of chemotherapy or chemoradiotherapy.
- Patients will be asked to donate blood samples at various time points before and during their treatment and once every 3 months post-treatment for up to 2 years, depending on the path of their disease. These blood samples will be taken at time of normal blood work.
- Allow access to fixed tumour tissue blocks, which had been developed from tissue taken during the standard surgery.
Control patients with acute pancreatitis admitted to hospital for observation or treatment.
- A single blood sample will be taken in conjunction with regular blood work during their hospital admission period.
Where’s this trial being run?Beacon Hospital, Beaumont Hospital, Bon Secours Cork, Tallaght University Hospital, St Vincents University Hospital, University Hospital Galway, and University Hospital Waterford
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
|Name:||PDAC Plasma Biomarker|
Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma.
|Principal Investigator:||Prof Ray McDermott (Tallaght Hospital)|
Cancer Trials Ireland.
Global: Not Applicable
Ireland: December 2013
|Global Recruitment Target:||Not Applicable|
|Ireland Recruitment Target:||240|